Pyros Pharmaceuticals
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Pyros Pharmaceuticals was a specialty pharmaceutical company founded in 2017 in Parsippany, New Jersey by Michael Smith and Edwin Urrutia, focused on medicines for rare pediatric diseases and underserved patients. Its lead product was VIGAFYDE (vigabatrin) oral solution - the first and only ready-to-use vigabatrin formulation, and the first new product approved for infantile spasms in 15 years (FDA approved June 17, 2024, launched September 2024). It raised about $880,000 in seed funding across two rounds.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Michael Smith and Edwin Urrutia founded Pyros Pharmaceuticals in Parsippany, NJ, to develop medicines for rare pediatric diseases.
- FDA approval for VIGAFYDE
On June 17, 2024 the FDA approved VIGAFYDE (vigabatrin) oral solution for infantile spasms in pediatric patients 1 month to 2 years; it launched in September 2024.
- Acquired by Bora Pharmaceuticals
In November 2024 Bora Pharmaceuticals (TWSE: 6472) acquired Pyros Pharmaceuticals to expand its rare-disease portfolio, citing synergies with its recent Upsher-Smith purchase in the pediatric CNS space.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.